Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Absci (NASDAQ:ABSI) has announced a strategic collaboration with Oracle Cloud Infrastructure (OCI) and AMD to enhance its AI-driven drug discovery platform. The partnership leverages OCI's AI infrastructure and AMD's latest hardware, including next-generation Instinct™ MI355X GPUs, to accelerate biologics design cycles and reduce costs.
The collaboration enables Absci to perform large-scale molecular-dynamics simulations and end-to-end antibody design with improved efficiency. Using OCI's bare metal instances powered by 5th Generation AMD EPYC™ processors, Absci has achieved ultra-low latency of 2.5 µs and terabytes-per-second throughput for data processing.
Absci (NASDAQ:ABSI) ha annunciato una collaborazione strategica con Oracle Cloud Infrastructure (OCI) e AMD per potenziare la sua piattaforma di scoperta di farmaci guidata dall'AI. La partnership sfrutta l'infrastruttura AI di OCI e l'hardware più recente di AMD, compresi i GPU di nuova generazione Instinct™ MI355X, per accelerare i cicli di progettazione dei biologici e ridurre i costi.
La collaborazione consente ad Absci di eseguire simulazioni su larga scala della dinamica molecolare e progettazione end-to-end di anticorpi con maggiore efficienza. Grazie alle istanze bare metal di OCI basate su processori AMD EPYC™ di 5ª generazione, Absci ha raggiunto una latenza ultra-bassa di 2,5 µs e una capacità di throughput di terabyte al secondo per l'elaborazione dei dati.
Absci (NASDAQ:ABSI) ha anunciado una colaboración estratégica con Oracle Cloud Infrastructure (OCI) y AMD para mejorar su plataforma de descubrimiento de fármacos impulsada por IA. La alianza aprovecha la infraestructura de IA de OCI y el hardware más reciente de AMD, incluidos los GPUs de próxima generación Instinct™ MI355X, para acelerar los ciclos de diseño de biológicos y reducir costes.
La colaboración permite a Absci realizar simulaciones a gran escala de dinámica molecular y diseño de anticuerpos de extremo a extremo con mayor eficiencia. Usando instancias bare metal de OCI con procesadores AMD EPYC™ de 5.ª generación, Absci ha conseguido una latencia ultra baja de 2,5 µs y un rendimiento de terabytes por segundo en el procesamiento de datos.
Absci (NASDAQ:ABSI)는 AI 기반 신약 개발 플랫폼을 강화하기 위해 Oracle Cloud Infrastructure (OCI) 및 AMD와 전략적 협력을 발표했습니다. 이 파트너십은 OCI의 AI 인프라와 AMD의 최신 하드웨어, 차세대 Instinct™ MI355X GPU 등을 활용해 바이오 의약품 설계 주기를 단축하고 비용을 절감합니다.
이번 협력을 통해 Absci는 대규모 분자 동역학 시뮬레이션과 엔드투엔드 항체 설계를 더 높은 효율로 수행할 수 있게 되었습니다. 5세대 AMD EPYC™ 프로세서 기반의 OCI 베어메탈 인스턴스를 사용하여 Absci는 2.5 µs의 초저지연과 초당 테라바이트 단위의 데이터 처리 처리량을 달성했습니다.
Absci (NASDAQ:ABSI) a annoncé une collaboration stratégique avec Oracle Cloud Infrastructure (OCI) et AMD pour améliorer sa plateforme de découverte de médicaments pilotée par l'IA. Le partenariat exploite l'infrastructure IA d'OCI et le matériel le plus récent d'AMD, y compris les GPU de nouvelle génération Instinct™ MI355X, afin d'accélérer les cycles de conception de biologiques et de réduire les coûts.
Cette collaboration permet à Absci d'effectuer des simulations de dynamique moléculaire à grande échelle et un design d'anticorps de bout en bout avec une plus grande efficacité. En utilisant des instances bare metal d'OCI équipées de processeurs AMD EPYC™ de 5e génération, Absci a atteint une latence ultra-faible de 2,5 µs et un débit de traitement de données de téraoctets par seconde.
Absci (NASDAQ:ABSI) hat eine strategische Zusammenarbeit mit Oracle Cloud Infrastructure (OCI) und AMD angekündigt, um seine KI-gestützte Wirkstoffforschungsplattform zu verbessern. Die Partnerschaft nutzt OCIs KI-Infrastruktur und AMDs neueste Hardware, darunter die Next‑Generation‑GPUs Instinct™ MI355X, um Designzyklen für Biologika zu beschleunigen und Kosten zu senken.
Die Kooperation ermöglicht es Absci, großskalige molekulardynamische Simulationen und End-to-End-Antikörperdesign effizienter durchzuführen. Mit OCI Bare‑Metal‑Instanzen, angetrieben von AMD EPYC™ Prozessoren der 5. Generation, erzielte Absci eine ultra‑niedrige Latenz von 2,5 µs und Terabyte‑pro‑Sekunde Durchsatz bei der Datenverarbeitung.
- Implementation of advanced AI infrastructure for accelerated drug discovery
- Reduced inter-GPU latency to as low as 2.5 µs
- Enhanced computational capabilities through Oracle and AMD partnership
- Improved efficiency in biologics design cycles
- None.
Insights
Absci's partnership with Oracle and AMD significantly boosts their AI drug discovery capabilities, potentially accelerating development timelines and reducing costs.
Absci's collaboration with Oracle Cloud Infrastructure (OCI) and AMD represents a substantial technological upgrade for their AI Drug Creation Platform. By leveraging OCI's bare metal instances powered by AMD EPYC processors and Instinct MI355X GPUs, Absci has achieved impressive technical improvements - reducing inter-GPU latency to as little as 2.5 µs and gaining terabytes-per-second throughput for data operations.
These infrastructure enhancements directly address critical bottlenecks in computational drug discovery. The partnership enables Absci to run large-scale molecular dynamics simulations with significantly higher resolution and performance, which is essential for accurately modeling complex antibody-antigen interactions. This capability is particularly valuable for a clinical-stage biotech company like Absci that's focused on biologics - large, complex therapeutic proteins that typically require extensive computational resources to design and optimize.
The technical foundation provided by this collaboration could meaningfully accelerate Absci's biologics design cycles while simultaneously reducing infrastructure costs. For a biotech company, shortening development timelines can significantly impact both cash runway and competitive positioning. By consolidating their infrastructure on OCI with AMD hardware, Absci is positioning themselves to potentially bring novel therapeutics to patients faster while optimizing their operational efficiency.
This partnership demonstrates Absci's commitment to leveraging cutting-edge computational infrastructure to advance their AI-driven drug discovery platform, potentially enhancing their ability to design effective biologics with greater speed and precision than traditional methods allow.
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs
AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.
To advance Absci’s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate the development and operations of its AI Drug Creation Platform, including large‑scale molecular‑dynamics (MD) simulations and end‑to‑end antibody design. Absci is building on this success with OCI and partnering with AMD to further boost the performance and scalability of its AI Drug Creation Platform with AMD’s next generation Instinct™ MI355X GPUs.
“Our mission is to push the boundaries of how we design new therapeutics,” said Sean McClain, Founder and CEO, Absci. “With OCI and AMD, we are pairing our cutting-edge AI models with best‑in‑class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI‑powered drug‑discovery workflows.”
Scaling AI-driven drug discovery with OCI and AMD
OCI’s bare metal instances, powered by 5th Generation AMD EPYC™ processors and ultrafast RDMA cluster networking, give Absci the low-latency networking and throughput needed for large-scale model training and high-resolution molecular-dynamics simulations that refine antibody–antigen interactions. With direct, bare-metal access to AMD GPUs in a single, flat-network supercluster, Absci has been able to eliminate hypervisor overhead, reduce inter-GPU latency to as little as 2.5 µs, and benefit from terabytes-per-second throughput for checkpointing and data streaming.
“Absci’s generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for,” said Dan Spellman, vice president, AI and OCI, Healthcare & Life Sciences, Oracle. “By combining bare metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we’re providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design.”
“Absci is demonstrating how AI can transform the pace of drug discovery, and we’re proud to support that mission,” said Ram Peddibhotla, corporate vice president, Data Center GPU Cloud Business, AMD. “By combining OCI with AMD EPYC CPUs, AMD Instinct GPUs and our open ROCm software platform, this collaboration provides the performance and scalability needed to advance complex biologics design and support more efficient discovery workflows.”
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
About AMD
For more than 55 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ:AMD) website, blog, LinkedIn, Facebook and X pages.
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Trademarks
AMD, EPYC, AMD Instinct, ROCm and combinations thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
Contact Info
Absci
press@absci.com
David Szabados
AMD Communications
david.szabados@amd.com
Julia Allyn
Oracle
julia.allyn@oracle.com
FAQ
What is the partnership between Absci, Oracle, and AMD focused on?
How does Oracle Cloud Infrastructure benefit Absci's drug discovery process?
What specific AMD technology is Absci using in this collaboration?
What performance improvements has Absci achieved through this collaboration?
How will this technology partnership impact Absci's drug development timeline?
